| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| ln Vitro |
- 25,26-Dihydroxyvitamin D3 (also known as 25,26-dihydroxycholecalciferol) exhibited intestinal calcium transport activity in vitro. Using everted gut sacs from vitamin D-deficient rats, the compound significantly stimulated calcium uptake compared to the control group. Its activity was approximately 60% of that of 1,25-dihydroxyvitamin D3 (the active form of vitamin D3) at equivalent concentrations [1]
|
|---|---|
| ln Vivo |
- In vitamin D-deficient rats, subcutaneous administration of 25,26-Dihydroxyvitamin D3 (1.25, 2.5, and 5 μg per rat daily for 7 days) dose-dependently increased serum calcium concentrations. The highest dose (5 μg/rat) elevated serum calcium from 5.8 ± 0.3 mg/dL (control) to 9.2 ± 0.4 mg/dL, approaching the normal serum calcium level (10–11 mg/dL) [2]
- The compound significantly increased intestinal calcium absorption in vitamin D-deficient rats, as determined by the balance study. At 5 μg/rat daily, calcium absorption rate was increased by 45% compared to the control group [2] - 25,26-Dihydroxyvitamin D3 enhanced bone calcium content in vitamin D-deficient rats. After 7 days of treatment with 5 μg/rat daily, bone calcium concentration was increased by 32% compared to the control group, although it was lower than that induced by 24,25-dihydroxyvitamin D3 at the same dose [2] - In human subjects, 25,26-Dihydroxyvitamin D3 was detected in circulating plasma at a concentration range of 1.2–4.5 ng/mL in healthy adults, indicating endogenous production as a metabolite of vitamin D3 [3] |
| Animal Protocol |
- Vitamin D-deficient rat model establishment: Rats were fed a vitamin D-free diet and kept in a dark environment for 4 weeks to induce vitamin D deficiency, confirmed by low serum calcium (< 7 mg/dL) and phosphorus (< 4 mg/dL) levels [2]
- In vivo biological activity assay: Vitamin D-deficient rats were randomly divided into control group (vehicle subcutaneous injection) and 25,26-Dihydroxyvitamin D3 treatment groups (1.25, 2.5, 5 μg per rat daily). The compound was dissolved in ethanol and diluted with saline (final ethanol concentration < 5%), administered subcutaneously once daily for 7 days. Serum calcium, phosphorus, intestinal calcium absorption, and bone calcium content were measured after the treatment period [2] - Intestinal calcium transport in vitro assay: Everted gut sacs were prepared from the jejunum of vitamin D-deficient rats. The sacs were incubated in a buffer containing 25,26-Dihydroxyvitamin D3 (10⁻⁸–10⁻⁶ M) and radioactive calcium. After incubation for 1 hour, the radioactivity in the serosal fluid was measured to calculate calcium transport rate [1] |
| References |
|
| Additional Infomation |
25,26-Dihydroxyvitamin D3 is an endogenous metabolite of vitamin D3, formed by the 26-hydroxylation of 25-hydroxyvitamin D3[1][2][3]. Its main biological function is to regulate calcium metabolism by promoting intestinal calcium transport and increasing bone calcium deposition[1][2]. The biological activity of 25,26-dihydroxyvitamin D3 is weaker than that of 1,25-dihydroxyvitamin D3, but it is comparable to 24,25-dihydroxyvitamin D3 in terms of calcium regulation[2]. A radioimmunoassay has been established to determine circulating 25,26-dihydroxyvitamin D3 in human plasma, which is helpful for studying its physiological functions and metabolism[3].
|
| Molecular Formula |
C27H44O3
|
|---|---|
| Molecular Weight |
416.63646
|
| Exact Mass |
416.329
|
| CAS # |
29261-12-9
|
| PubChem CID |
21159907
|
| Appearance |
White to off-white solid powder
|
| Density |
1.06g/cm3
|
| Boiling Point |
575.3ºC at 760mmHg
|
| Flash Point |
243.7ºC
|
| Vapour Pressure |
1.24E-15mmHg at 25°C
|
| Index of Refraction |
1.548
|
| LogP |
5.706
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
30
|
| Complexity |
678
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C[C@H](CCCC(C)(CO)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C
|
| InChi Key |
QOWCBCXATJITSI-ZLNGONTQSA-N
|
| InChi Code |
InChI=1S/C27H44O3/c1-19-9-12-23(29)17-22(19)11-10-21-8-6-16-27(4)24(13-14-25(21)27)20(2)7-5-15-26(3,30)18-28/h10-11,20,23-25,28-30H,1,5-9,12-18H2,2-4H3/b21-10+,22-11-/t20-,23+,24-,25+,26?,27-/m1/s1
|
| Chemical Name |
(6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-1,2-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~240.02 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4002 mL | 12.0008 mL | 24.0015 mL | |
| 5 mM | 0.4800 mL | 2.4002 mL | 4.8003 mL | |
| 10 mM | 0.2400 mL | 1.2001 mL | 2.4002 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
